Pathways of Targeted Therapy for Colorectal Cancer
Abstract
One of the most common and deadly cancers in the world, colorectal cancer (CRC) caused around 881,000 melanoma deaths in 2018. The third most frequent cause overall cancer-related death worldwide is colorectal cancer (CRC). A difficult issue related to chemotherapy is the subsequent adverse effects brought on by the toxicity of conventional medications. Location-specific/targeted distribution of chemotherapeutic medicines precisely to the afflicted site of something like the colon in a foreseeable and reliable way is obviously of concern. For many years, cancer sufferers' initial choices have been surgery and chemotherapy. The prognosis for CRC, particularly for those with metastatic tumours, has never been satisfactory. A recent optional strategy called targeted therapy has been effective in extending patients with CRC's overall survival. Following achievements with the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab, new drugs that inhibit several important pathways and immune checkpoints are being developed at an unheard-of rate. The growing number of high-quality clinical trials is being used as a basis for updating guidelines worldwide regarding the recommended targeted medications. An overview of current CRC-targeted drugs and their underlying processes is given in this review, along with a discussion of their drawbacks and potential directions.
Keywords: Colorectal cancer, Chemotherapeutic medicines, Bevacizumab, Cetuximab,
Keywords:
Colorectal cancer, Chemotherapeutic medicines, Bevacizumab, CetuximabDOI
https://doi.org/10.22270/jddt.v12i5.5602References
Bray F et al., Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2018; 68:394-424.https://doi.org/10.3322/caac.21492
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet, 2019; 394:1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0
Kuipers EJ, et al., Colorectal cancer. Nat Rev Dis Prim., 2015; 1: 15065. https://doi.org/10.1038/nrdp.2015.65
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol., 2019; 16:713-732. https://doi.org/10.1038/s41575-019-0189-8
Sanchez-Gundin J, Fernandez-Carballido AM, Martinez-Valdivieso L, BarredaHernandez D, Torres-Suarez AI. New trends in the therapeutic approach to metastatic colorectal cancer. Int J Med Sci., 2018; 15:659-665. https://doi.org/10.7150/ijms.24453
Wolf AMD, et al., Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin., 2018; 68:250-281. https://doi.org/10.3322/caac.21457
Van der Stok EP, Spaander MCW, Grunhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 2017; 14:297-315. https://doi.org/10.1038/nrclinonc.2016.199
Messersmith WA. NCCN guidelines updates: management of metastatic colorectal cancer. J Natl Compr Cancer Netw., 2019; 17:599-601.
Brown KGM, Solomon MJ, Mahon K, O'Shannassy S. Management of colorectal cancer. British Med J., 2019; 366: l4561. https://doi.org/10.1136/bmj.l4561
Labianca R, et al., Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2013; 24(6):vi64-vi72. https://doi.org/10.1093/annonc/mdt354
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol., 2014; 25(3):iii1-iii9. https://doi.org/10.1093/annonc/mdu260
Seymour MT, et al., Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370:143-152. https://doi.org/10.1016/S0140-6736(07)61087-3
Koopman M, et al., Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007; 370:135-142. https://doi.org/10.1016/S0140-6736(07)61086-1
Colucci G, et al., Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol., 2005; 23:4866-4875. https://doi.org/10.1200/JCO.2005.07.113
Tournigand C, et al., FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol., 2004; 22:229-237. https://doi.org/10.1200/JCO.2004.05.113
Sundari A, Jayakumararaj R, Herbal remedies used to treat skin disorders in Arasankulam region of Thoothukudi District in Tamil Nadu, India Journal of Drug Delivery and Therapeutics, 2020; 8(5):33-38. https://doi.org/10.22270/jddt.v10i5.4277
Falcone A, et al., Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol., 2007; 25:1670-1676. https://doi.org/10.1200/JCO.2006.09.0928
Souglakos J, et al., FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer., 2006; 94:798-805. https://doi.org/10.1038/sj.bjc.6603011
Brodsky FM. Monoclonal antibodies as magic bullets. Pharm Res., 1988; 5:1-9.
Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharm., 2018; 834:188-196. https://doi.org/10.1016/j.ejphar.2018.07.034
Oh DY, Bang YJ. HER2-targeted therapies-a role beyond breast cancer. Nat Rev Clin Oncol., 2020; 17:33-48. https://doi.org/10.1038/s41571-019-0268-3
Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov., 2018; 17:353-377. https://doi.org/10.1038/nrd.2018.21
Tariman JD. Changes in cancer treatment: Mabs, Mibs, Mids, Nabs, and Nibs. Nurs. Clin N Am., 2017; 52:65-81. https://doi.org/10.1016/j.cnur.2016.10.004
Tiwari A, Saraf S, Verma A, Panda PK, Jain SK. Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World J Gastroenterol., 2018; 24:4428-4435. https://doi.org/10.3748/wjg.v24.i39.4428
Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev., 2018; 62: 50-60. https://doi.org/10.1016/j.ctrv.2017.11.002
Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med., 2011; 17:347-362. https://doi.org/10.1016/j.molmed.2011.01.015
Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013; 13:871-882. https://doi.org/10.1038/nrc3627
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med., 2003; 9:669-676. https://doi.org/10.1038/nm0603-669
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med., 1971; 285:1182-1186. https://doi.org/10.1056/NEJM197111182852108
Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol., 2002; 2:116-126. https://doi.org/10.1038/nri727
Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017; 152:357-371. https://doi.org/10.1111/imm.12788
Chen L Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest., 2015; 125:3384-3391. https://doi.org/10.1172/JCI80011
Arteaga CL, Engelmann JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014; 25: 282-303. https://doi.org/10.1016/j.ccr.2014.02.025
Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013; 13:663-673. https://doi.org/10.1038/nrc3559
Roskoski R. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharm Res., 2019; 139: 395-411. https://doi.org/10.1016/j.phrs.2018.11.014
Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. EGFR-targeted therapy. Exp Cell Res., 2011; 317:2765-2771. https://doi.org/10.1016/j.yexcr.2011.08.021
Wang Z. ErbB receptors and cancer. Methods Mol Biol., 2017; 1652:3-35. https://doi.org/10.1007/978-1-4939-7219-7_1
Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev., 2016; 35:575-588. https://doi.org/10.1007/s10555-016-9649-6
Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017; 17: 637-658. https://doi.org/10.1038/nrc.2017.84
Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharm Res., 2014; 79:34-74. https://doi.org/10.1016/j.phrs.2013.11.002
Hayes DF. HER2 and breast cancer-a phenomenal success story. N Engl J Med., 2019; 381:1284-1286. https://doi.org/10.1056/NEJMcibr1909386
Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014; 17:1-12. https://doi.org/10.1007/s10120-013-0252-z
Takegawa N, Yonesaka K. HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer. 2017; 16:247-251. https://doi.org/10.1016/j.clcc.2017.03.001
Kiavue N, et al., ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 2019. https://doi.org/10.1038/s41388-019-1001-5
Veikkolainen V, et al., Function of ERBB4 is determined by alternative splicing. Cell Cycle. 2011; 10:2647-2657. https://doi.org/10.4161/cc.10.16.17194
Junttila TT, et al., Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res., 2005; 65:1384-1393. https://doi.org/10.1158/0008-5472.CAN-04-3150
Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol., 2019; 12:63. https://doi.org/10.1186/s13045-019-0759-9
Cheng F, Guo D. MET in glioma: signaling pathways and targeted therapies. J Exp Clin Cancer Res., 2019; 38: 270. https://doi.org/10.1186/s13046-019-1269-x
Demkova L, Kucerova L. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol Cancer. 2018; 17:26. https://doi.org/10.1186/s12943-018-0795-z
Lam BQ, Dai L, Qin Z. The role of HGF/c-MET signaling pathway in lymphoma. J Hematol Oncol., 2016; 9: 135. https://doi.org/10.1186/s13045-016-0366-y
Bradley CA, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol., 2017; 14:562-576. https://doi.org/10.1038/nrclinonc.2017.40
Cooper CS, et al., Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984; 311:29-33. https://doi.org/10.1038/311029a0
Nakamura T, et al., Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342:440-443. https://doi.org/10.1038/342440a0
Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblastderived modulator of epithelial cell mobility. Nature. 1987; 327: 239-242. https://doi.org/10.1038/327239a0
Schmidt C, et al., Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995; 373: 699-702. https://doi.org/10.1038/373699a0
Anestis A, Zoi I, Karamouzis MV. Current advances of targeting HGF/c-Met pathway in gastric cancer. Ann Transl Med., 2018; 6:247. https://doi.org/10.21037/atm.2018.04.42
Safaie QE, et al., The c-Met receptor: implication for targeted therapies in colorectal cancer. Tumour Biol., 2017; 39:1010. https://doi.org/10.1177/1010428317699118
Otte JM et al., Functional expression of HGF and its receptor in human colorectal cancer. Digestion. 2000; 61:237-246. https://doi.org/10.1159/000007764
Strosberg JR, et al., A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012; 48:997-1003. https://doi.org/10.1016/j.ejca.2012.02.056
Berlin J, et al., A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res., 2013; 19:258-267. https://doi.org/10.1158/1078-0432.CCR-12-1800
Villalba M, Evans SR, Vidal-Vanaclocha F, Calvo A. Role of TGF-beta in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res., 2017; 370: 29-39. https://doi.org/10.1007/s00441-017-2633-9
Ghosh N, Hossain U, Mandal A, Sil PC. The Wnt signaling pathway: a potential therapeutic target against cancer. Ann NY Acad Sci., 2019; 1443:54-74. https://doi.org/10.1111/nyas.14027
Guinney J, et al., The consensus molecular subtypes of colorectal cancer. Nat Med., 2015; 21:1350-1356.
Published



How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).